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It was more than ﬁ ve decades ago when cellular repro-
gramming was ﬁ rst shown by somatic cell nuclear 
transfer. Th ese seminal experiments show that somatic 
cells can revert to pluripotency by somatic cell nuclear 
transfer, proving the totipotency of their genome. 
Th rough later studies we learned that somatic cell fate is 
mainly driven by a speciﬁ c set of transcription factors 
and solidiﬁ ed by epigenetic mechanisms, which can be 
reverted by reprogramming activities in oocytes or 
embryonic stem cells. Th e knowledge gained in the past 
half a century culminated in the breakthrough discovery 
of induced pluripotency by Yamanaka and Takahashi in 
2006 [1]. Th ey demonstrated that terminally diﬀ eren-
tiated cells can return to an embryonic-like pluripotent 
state (termed induced pluripotent stem cells (iPSCs)) by 
forced expression of four transcription factors (Oct4, 
Sox2, Klf4 and c-Myc) [1]. iPSC technology has since 
spurred a plethora of studies aimed at understanding the 
mechanism of reprogramming, modeling human diseases 
and developing cell-based therapies for degenerative 
conditions.
Despite great enthusiasm and eﬀ ort, iPSC-related 
research is hampered by the fact that iPSC generation is a 
slow and ineﬃ  cient process, and that most iPSC 
derivation protocols entail modiﬁ cations of the host 
genome. Th e most widely adopted method for generating 
iPSCs relies on integrating retroviral vectors. Th e process 
takes approximately 4 weeks and only 0.01 to 0.1% of the 
cells become iPSCs. In addition, there are serious con-
cerns regarding the safety of these virally derived iPSCs. 
Th e integrated proviruses may cause insertional muta-
genesis, bias the diﬀ erentiation potential of iPSCs if not 
silenced, and lead to tumor formation once reactivated 
during the diﬀ erentiation process [2]. People have tried 
to avoid these issues by generating transgene-free iPSCs 
using diﬀ erent strategies, including non-integrative 
vectors, excisable vectors, and cell-penetrating proteins. 
Th e DNA-based methods that are ostensibly non-
integrating still require careful characterization of the 
iPSC genome to rule out random integration of small 
fragments of the vector. Th e removal of excisable vectors 
entails complex manipulations and prolonged culture, 
and still leaves a ‘scar’ in the genome in many cases. 
Moreover, none of the above mentioned technologies 
resolve the issue of slow kinetics and low eﬃ  ciency of 
iPSC generation [3].
Can the ‘three wishes’ - safety, speed and eﬃ  ciency - of 
reprogramming ever be fulﬁ lled? A recent paper by 
Warren and colleagues [4] may have just provided an 
answer. Th e innovation of the study is centered on the 
use of synthetic mRNA, a previously underexplored route 
for delivery of reprogramming factors, in iPSC gener a-
tion. In contrast to DNA-based vectors, the use of mRNA 
completely eliminates the risk of modifying the host 
genome. It has several advantages over the protein trans-
duction approach: it is simpler and more eﬃ  cient, as one 
mRNA molecule is likely to undergo multiple rounds of 
translation before its degradation; and the proteins 
produced inside the cell have proper post-translational 
modiﬁ cations, resulting in more precise localization and 
higher activity. Indeed, mRNA-based gene delivery has 
been shown to be highly eﬃ  cient in human stem and 
Abstract
Recent development of a synthetic mRNA-based 
technology for effi  cient reprogramming to 
pluripotency and cell fate conversion without any 
modifi cation to the genome has generated great 
interest among researchers and clinicians alike. It is 
hoped that this technology could contribute to unmet 
needs on several fronts of regenerative medicine, 
including mechanistic study of reprogramming, 
generation of safe induced pluripotent stem cells 
suitable for clinical applications, and derivation of 
desired cell types for cell-replacement therapy. We 
will discuss the technological advancements made 
by this synthetic mRNA methodology, its implications, 
as well as the challenges that lie ahead in the fi eld of 
regenerative medicine.
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progenitor cells [5]. Furthermore, its safety has been 
demonstrated in clinical trials [6]. However, there are two 
major roadblocks to adapting this methodology to 
cellular reprogramming. First, mRNAs are rapidly turned 
over in the cell, which is incompatible with the 
requirement for sustained expression of reprogramming 
factors for about 2 weeks. Th is point is clearly illustrated 
in a recent study by Plews and colleagues [7] in which a 
single electroporation of mRNAs encoding OCT4, SOX2, 
KLF4, c-Myc and SV40 large T antigen resulted in only 
partially reprogrammed cells. After careful examination 
of the kinetics of reprogramming factor levels after 
mRNA transfection, Warren and colleagues [4] con-
cluded that daily transfection is necessary to maintain the 
reprogram ming activities. Consequently, this strategy 
leads to the second caveat, which is the high cytotoxicity 
triggered by repeated transfection of foreign mRNA via 
an NF-κB-dependent anti-viral pathway. Th rough careful 
experi men tation, the authors overcame these issues by 
intro ducing a series of changes to the standard protocol 
to reduce the immunogenecity of synthetic RNA 
(removal of 5’ triphosphates, incorporation of modiﬁ ed 
ribo nucleo sides) and to suppress interferon signaling 
pathways (media supplementation of interferon inhibitor 
B18R). Armed with these innovations, they successfully 
developed an mRNA-based reprogramming protocol 
that is two times faster and 35-fold more eﬃ  cient than 
the viral one. Moreover, the global gene expression 
proﬁ le of RNA-induced pluripotent stem cells (RiPSCs) 
more closely resembles human embryonic stem cells than 
virally derived iPSCs. As the authors pointed out, such a 
diﬀ erence may be attributed to the absence of transgenes 
in RiPSCs. However, it is worth pointing out that other 
factors, such as the culture conditions that the cells are 
exposed to during reprogramming as well as the passage 
number of iPSCs, are known to aﬀ ect the epigenetic state 
of iPSCs.
As shown in this study and others, the mRNA-based 
methodology also applies to directed diﬀ erentiation of 
iPSCs and direct fate conversion between terminally 
diﬀ erentiated cells. Other than improving eﬃ  ciency and 
safety of existing protocols, the mRNA-based technology 
can aid in the development of better protocols that 
ensure stable and complete conversion to the desired cell 
types, which are independent of exogenous factors. In 
other situations, synthetic mRNAs may be used to alter 
cell fate temporarily. For example, gene targeting by 
homologous recombination is extremely ineﬃ  cient in 
human iPSCs, but it can be greatly improved in the naïve 
pluripotent state. However, such a state in human iPSCs 
requires overexpression of Oct4, Klf4 and Klf2 [8]. It is 
conceivable that these factors can be delivered as mRNA 
to induce the naïve pluripotent state without any 
modiﬁ cations to the genome.
Th e synthetic mRNA technology developed by Warren 
and colleagues represents one of the few examples of 
major technical advancements in regenerative medicine. 
It is likely to accelerate the study of the mechanism of 
cellular reprogramming and the translation of research 
ﬁ ndings into clinical practice. While being optimistic, we 
should also remain vigilant in studying the safety of the 
cells derived by this technology. For example, further 
studies are necessary to make sure that repeated 
transfections and prolonged inhibition of interferon 
signaling do not cause any lasting change in the cells or 
constitute a selection pressure for cells that are deﬁ cient 
in innate immune response. More importantly, we and 
others recently showed that iPSCs derived by existing 
protocols (including RiPSCs) are equally prone to the 
accumulation and positive selection of mutations in 
tumor suppressor genes, oncogenes and genes important 
for cell cycle regulation [9,10]. It is then logical to assume 
that not only does a great deal of research eﬀ ort have to 
be focused on the development of eﬃ  cient non-
integrative approaches but also on novel methods limit-
ing the accumulation of harmful mutations during the 
reprogramming process.
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